@dbranderMD Profile picture

Danielle M. Brander

@dbranderMD

translational oncologist at Duke Cancer Institute / director CLL & Lymphoma research program / views and tweets are my own

Joined December 2019
Similar User
Chaitra Ujjani, MD photo

@UjjaniC

Matthew Davids, MD, MMSc photo

@DrMDavids

Jeff Sharman photo

@jeff_sharman

CLL Society Inc. photo

@CllSociety

Alan Skarbnik photo

@ASkarbnik

Craig Moskowitz, MD photo

@CraigMoskMD

Danilov Lab photo

@DanilovLab

Joanna M. Rhodes, MD, MSCE photo

@drjoannarhodes1

Soni Smith MD photo

@SoniSmithMD

Deborah Stephens photo

@DebbieMStephens

Mark Roschewski photo

@RoschewskiMD

Mazyar Shadman, MD MPH photo

@mshadman

Daniel Persky, MD photo

@DrDanPersky

Adam Kittai photo

@AdamKittai

Krish Patel photo

@KrishPatelMD

Danielle M. Brander Reposted

CME Opportunity: Join #DukeDebates2024, presented by #DukeCancerNetwork in collaboration with @DukeCancer April 12-14, 2024, Hilton Head, SC Register here: bit.ly/DukeDebates CME credit available. Earn up to 12 MOC Part 2 points. #DukeCancerInstitute #MedEd

Tweet Image 1

Danielle M. Brander Reposted

Ask your doctor if you are considered high risk by the CLLIPI score. If so, you may qualify for this exciting study. #CLL @SWOG @BrianHill_MDPhD @mshadman @anthonymatomd @dbranderMD @DanilovLab

Venetoclax + obinutuzumab combo is approved as front-line tx for pts w #CLL. Can intervening early w this combo vs waiting for symptoms lengthen survival for pts w high-risk (CLL-IPI of 4+) CLL or small #lymphocytic #lymphoma? @SWOG S1925 trial. SWOG.org/clinical-trial… @NRGonc

Tweet Image 1


Danielle M. Brander Reposted

Outstanding commentary by ⁦@DebbieMStephens⁩ from ⁦@huntsmancancer⁩ on the recent publication on the ELEVATE-RR study comparing ibrutinib and acalabrutinib in R/R CLL in ⁦@JCO_ASCOascopubs.org/doi/abs/10.120…


Danielle M. Brander Reposted

We are making progress in high-risk #CLL. Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions and/or Mutations | Blood | American Society of Hematology #leusm #leukemia @UKKoeln ashpublications.org/blood/article/…

Tweet Image 1

Danielle M. Brander Reposted

Just out - our multicenter effort to dissect comorbidities in CLL ⁦@mshadman⁩ ⁦@DrDanPersky⁩ ⁦@dbranderMD⁩ ⁦@matthew_mei⁩ ⁦@jonathonbcohen⁩ ⁦@KrishPatelMD⁩ ⁦@BrianHill_MDPhD⁩ ⁦@DebbieMStephensclincancerres.aacrjournals.org/content/early/…


Danielle M. Brander Reposted

Thanks to the @CllSociety for all you do for our patients. Happy New Year!

To keep our CLL patients healthy, we use our Brains! 100s of ground-breaking CLL-focused clinical trials & 1000s of hours of compassionate clinical care inform #CLLSociety’s Med Ad Board. Thank you! @DrMDavids @dbranderMD @DebbieMStephens @ASkarbnik bit.ly/2KpJ7A5

Tweet Image 1


Danielle M. Brander Reposted

Important MURANO tox ax @anthonymatomd @jeff_sharman et al 28% premature d/c VR<2y ⬇️ PFS in prem d/c ven for any reason (PD excluded;p<0.0001)+due to AE Interrupt for AE 69% / dose ⬇️ 23% both no impact on PFS/OS Tox mx+continued Rx important for VenR PFS outcome #CLL #lymsm

Tweet Image 1
Tweet Image 2

Danielle M. Brander Reposted

#ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer Phase I trial incorporating NK cells for patients w/ #CML & MRD after TKI therapy. #leusm bit.ly/3osWQ7x

Tweet Image 1

There may not have been an official ASH run this year, but anyone else still get in their #FauciFour ? If daily running is the secret to Dr Fauci leading the nation through this chaos, may I never stop. Also, the San Diego skyline has nothing on my view. #IRunForASH

Tweet Image 1

To teach is to learn, twice And thankful for this opportunity from #ASH20, twice - to learn from so many others but also to work on this with an amazing fellow @DukeFellows, Dr Ashley Hanlon @amilliga, that has taught me so much and co authored this chapter #dukefamily

To keep our CLL patients healthy, we use our Brains! 100s of ground-breaking CLL-focused clinical trials & 1000s of hours of compassionate clinical care inform #CLLSociety’s Med Ad Board. Thank you! @DrMDavids @dbranderMD @DebbieMStephens @ASkarbnik bit.ly/2KpJ7A5

Tweet Image 1


Danielle M. Brander Reposted

We are so excited to welcome @_joycehwang @andrewpeseski @FahminB_MDPhD Drs. Kathrine DiNardo, Cameron Oswalt, Grayce Selig, and Cameron Wood to the Duke Heme/Onc Fellowship Program! We are so excited to have you join our wards and clinics in July 2021! @DukeCancer @dukemedicine


Intolerance is a failure of the medication for that given patient, patients don’t fail therapy. Grateful to be a part of this collaborative effort @DukeHMCT and for all trials aimed at the unmet need of intolerance. @anthonymatomd @AndreaSitlinger and many others

To keep our CLL patients healthy, we use our Brains! 100s of ground-breaking CLL-focused clinical trials & 1000s of hours of compassionate clinical care inform #CLLSociety’s Med Ad Board. Thank you! @DrMDavids @dbranderMD @DebbieMStephens @ASkarbnik bit.ly/2KpJ7A5

Tweet Image 1


Danielle M. Brander Reposted

Please see our publication of the largest cohort of patients #Hodgkin transformation in #CLL patients. haematologica.org/article/view/h… Planning more research in this patient population. Thanks for a great collaborative effort. @huntsmancancer @UUtah @UofUHealth


Danielle M. Brander Reposted

🎉🎉 Congratulations to @BarbAlexanderMD, who will be the new president of @IDSAInfo "The critical role of ID physicians & scientists has never been more apparent as it is today." idsociety.org/news--publicat…


every point exactly, @JasAWebb - easy to feel defeated hearing this news, but will take that energy and use it to inspire action towards the many challenges that face us...

To keep our CLL patients healthy, we use our Brains! 100s of ground-breaking CLL-focused clinical trials & 1000s of hours of compassionate clinical care inform #CLLSociety’s Med Ad Board. Thank you! @DrMDavids @dbranderMD @DebbieMStephens @ASkarbnik bit.ly/2KpJ7A5

Tweet Image 1


Danielle M. Brander Reposted

This is consistent with my observation in the hospital now: milder forms of #SARSCoV2 infections. #Masks may reduce the viral dose during contact with infected persons: Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine | NEJM nejm.org/doi/full/10.10…


Loading...

Something went wrong.


Something went wrong.